ST. PAUL, Minn. — Kindeva Drug Delivery L.P. (Kindeva) and Cambridge Healthcare Innovations Limited (CHI) have entered into a collaboration to develop and commercialize CHI’s αeolus dry-powder inhaler (DPI) platform technology. The collaboration will leverage Kindeva’s product development, regulatory affairs, and manufacturing capabilities in tandem with CHI’s DPI technology and device development expertise. To accelerate platform and product development, Kindeva and CHI will evaluate a range of drugs for the αeolus platform. This initial work will inform development programs undertaken in partnership with biopharmaceutical companies. Additionally, the initial drugs evaluated, subject to all required regulatory approvals, could become products to treat a range of respiratory diseases. The αeolus technology platform could also be used for the systemic delivery of drugs to the lungs, addressing a broader range of conditions.
Almost ready for #ddl2019
Almost ready for ddl2019… Looking forward to catching up with many old friends. ?
View on LinkedIn
One week to go
There are still tickets available if you’re quick!
One week to go before DDL2019 opens at the EICC for our big 30th birthday! We are busy collating and alphabetising 800+ badges! Registration is still open: don’t forget to book online at www.ddl-conference.com. See you in a week in Edinburgh!!!
View on LinkedIn
day at Intertek Melbourne
Warren Isaacs and I had a very productive day at Intertek Melbourne earlier this week, and spent almost seven hours gathering accurate pressure and flowrate data to calibrate our mathematical model. The rig behaved extremely well – thanks to John Hewett for making the rig, and initial data indicates that I’d underestimated the efficiency by almost a factor of two – in a good way! ? Lot’s more work to do now…
(Great that I could remember how to tie a constrictor knot – how else do you quickly seal 1 mm bore silicone tubing onto a 27G needle?!)
View on LinkedIn
calibration test rig
This is so exciting! Our calibration test rig should be available early next week. We can then find out what’s really going on inside our inhaler airway and optimise it. Once we’ve done this we’ll be generating NGI data to compare to reference inhaler products, and will be working on a complete platform device offering in time for DDL2019.
View on LinkedIn